advertisement
Editors Selection IGR 18-1
Basic research: Pharmacogenomics
Comment by Jonathan Crowston on:
18160 Association between genetic polymorphisms of the prostaglandin F2α receptor gene and response to latanoprost, Sakurai M; Higashide T; Takahashi M et al., Ophthalmology, 2007; 114: 1039-1045
The field of pharmacogenomics aims to personalize medicine to a patient's genotype so that drug selection can be tailored to an individual to optimize treatment response, while at the same time limiting the risk of adverse events.
Sakurai et al.(466)investigated the association between polymorphisms of the FP receptor gene (by DNA sequencing) and the short-term diurnal IOP response to topical latanoprost in 100 normal subjects. They found that two single nucleotide polymorphisms (SNP's) in the promoter and intron-1-portion of the FP receptor gene were associated with a diminished IOP response to latanoprost. Baseline IOPs were not different among the SNP genotypes.
The authors next used a luciferase gene-based promoter assay to examine the effects of these SNPs on gene transcription. Both SNPs significantly reduced FP receptor gene expression, providing a likely mechanism whereby the response to latanoprost is diminished. As the authors point out, further work is now needed to determine whether these SNPs are also associated with a diminished response to long-term topical PG therapy in glaucoma patients.
Comments
The comment section on the IGR website is restricted to WGA#One members only. Please log-in through your WGA#One account to continue.Log-in through WGA#One
